Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
Haruka MiyazakiDaisuke WatanabeNorihiro OkamotoEri TokunagaYuna KuHaruka TakenakaNamiko HoshiMakoto OoiYuzo KodamaPublished in: BMC gastroenterology (2022)
The 48-week continuation rate of anti-TNFα agents was 75.9% in bio-naïve patients with intestinal BD. However, a higher baseline CRP level (≥ 1 mg/dL) was associated with discontinuation of anti-TNFα agents.